Novo Nordisk taps OpenAI

Novo Nordisk said on April 14 it will roll out OpenAI tools across drug discovery, manufacturing and commercial teams to speed new medicine development. (biospace.com) The Danish drugmaker said the partnership will start with pilot programs in research and development, manufacturing and commercial units, with full integration targeted by the end of 2026. Novo said OpenAI will also help train employees to use the systems in daily work. (pharmaceutical-technology.com) Novo Chief Executive Mike Doustdar said the company wants to use artificial intelligence to analyze datasets “at a scale that was previously impossible,” spot patterns and test hypotheses faster. The company said the program will run under strict data-governance rules and human oversight. (cnbc.com) (biospace.com) Drug discovery starts with a basic problem: researchers must sift through huge volumes of lab results, genetic data and clinical records to decide which molecules are worth testing. Novo said it wants OpenAI’s systems to help identify promising drug candidates earlier and cut time between research and patient use. (cnbc.com) (biopharminternational.com) The deal lands as Novo tries to defend its position in obesity medicine against Eli Lilly, whose tirzepatide franchise has gained ground in the market. Reuters reported that Novo has fallen behind Lilly in the weight-loss category, even as Novo’s Ozempic and Wegovy remain two of the sector’s biggest brands. (reuters.com) (cnbc.com) That rivalry has shifted to pills as well as injections. Novo’s once-daily Wegovy pill won United States approval on December 22, 2025, and Eli Lilly’s oral obesity drug orforglipron, branded Foundayo, was approved in April 2026. (prnewswire.com) (biopharmadive.com) Novo was already expanding its artificial-intelligence stack before this week’s announcement. In June 2025, Nvidia said it was working with Novo Nordisk and Denmark’s Center for AI Innovation on models and agents for early research and clinical development using the Gefion supercomputer. (nvidianews.nvidia.com) (prnewswire.com) OpenAI has been building a healthcare client list of its own. Industry reports said the company had already signed life-sciences deals with Moderna, Sanofi and Formation Bio before adding Novo Nordisk. (manufacturingchemist.com) (fiercepharma.com) Novo did not disclose financial terms, but the company framed the agreement as an operating push as much as a research one: faster experiments, tighter production planning and quicker decisions across a business built around obesity and diabetes drugs. (bloomberg.com) (reuters.com)